Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET

Company Participants

Carrie Siragusa - VP of Marketing

Lonnel Coats - CEO

Tom Garner - Chief Commercial Officer

Craig Granowitz - Chief Medical Officer

Jeffrey Wade - President and CFO

Conference Call Participants

Andrew Tsai - Jefferies

Joseph Stringer - Needham & Company

Operator

Good day and welcome to the Lexicon Pharmaceuticals' Third Quarter 2023 Financial Results Conference Call. Today all participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note that today's event is being recorded.

I would now like to turn the conference over to Carrie Siragusa. Please go ahead.

Carrie Siragusa

Thank you, Chris. Good morning and welcome to the Lexicon Pharmaceuticals' third quarter 2023 financial results conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer and Tom Garner Lexicon Senior Vice President and Chief Commercial Officer.

Earlier this morning, Lexicon issued a press release announcing our financial results for the third quarter of 2023, which is available on our website at www.lexpharma.com and through our SEC filings. A webcast of this call along with a slide presentation is available on our website. During this call, we will review the information provided in the release, provide a corporate update, and then use the remainder of our time to answer your questions.

Before we begin, let me remind you that we will be making forward looking statements including statements relating to the safety, efficacy, clinical development, regulatory status and therapeutic and commercial potential of INPEFA, LX9211 and our other drug programs. These statements may also include characterizations and projections relating to our commercial launch of INPEFA in heart failure, as well as the clinical development, regulatory status and market opportunity for all of our drug programs.

This call may also contains forward-looking statements relating to our growth and future operating results, discovery and development of our drug candidates, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. Various risks may cause our actual results to differ materially from those expressed or implied in such forward-looking statements. These risks include uncertainties related to our commercial launch of INPEFA our discussions with the FDA and other regulatory authorities regarding our drug programs, the timing and results of clinical trials and preclinical studies of our drug candidates, our dependence upon strategic alliances and other third party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties, and the requirements of substantial funding to conduct our planned research, development and commercialization activities.